Solventum Corporation (SOLV) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Solventum Corporation  (NYSE: SOLV)


Solventum's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Solventum's ROI in the second quarter of 2026?
Solventum Corporation achieved a return on average invested assets (ROI) of 11.98 % in its second quarter of 2026 a new company high.

ROI has improved compared to 11.19% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 87 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 729, from total ROI ranking in the first quarter of 2026 at 770.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -6.26 % 5.23 % 9.35 % 8.41 % 40.93 %
Y / Y Net Income Change TTM 277.37 % 277.84 % 542.98 % 622.27 % 326.97 %
Investment (TTM) in Millions 10,580 12,136 12,731 12,435 13,905
Return On Investment (TTM) 11.98 % 11.19 % 11.89 % 11.75 % 2.98 %
SOLV's Overall Ranking # 729 # 770 # 640 # 1675 # 1643
Seq. Investment Change TTM -6.49 % -2.17 % 0.87 % 1.59 % 4.97 %
Seq. Net Income Change TTM 0.14 % -7.97 % 2.1 % 301.05 % 0.26 %
Net Income (TTM) in Millions 1,434 1,432 1,556 1,524 380

SOLV Company Profile >> Back to SOLV Roi Comparisons >> See Annual SOLV Return On Investment



Return On Investment SOLV's Ranking
Within: No.
Industry # 24
Sector # 88
Overall # 729

Return On Investment Statistics
High Average Low
11.98 %
8.13 %
2.98 %
(Jun 30 2026)   (Jun 30 2025)







Financial Statements
Solventum's II. Quarter Investments $ 10,580 Millions SOLV's Balance sheet
Solventum's II. Quarter Income $ 92 Millions Quarterly SOLV's Income Statement
SOLV's Income by Division See SOLV's Income by Division


SOLV Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024


Total Investments in Millions 10,765 12,280 0 0 0
Y / Y Investment Growth -12.34 % - - - -
Net Income in Millions 1,556 479 0 0 0
Y / Y Net Income Growth 224.84 % - - - -
Annual Return On Investment 14.45 % 3.9 % - - -


Annual Roi Comment
In the fiscal year 2025 ROI improved to 14.45 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SOLV's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SOLV's Competitors
Subscribers only: Roi for Solventum's Suppliers
Subscribers only: Return On Investment for SOLV's Customers

Other Ratios
SOLV's Roa SOLV's Inventory Turnover Ratio SOLV's Growth Rates SOLV's Dividend Statistics
SOLV's Profitability Ratios SOLV's Asset Turnover Ratio SOLV's Dividend Growth
SOLV's Roe SOLV's Valuation Ratios SOLV's Financial Strength Ratios SOLV's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %
Intuitive Surgical Inc   17.11 %
Theravance Biopharma inc   17.10 %
Standard Biotools Inc   16.38 %
Inspire Medical Systems inc   16.34 %

Date modified: 2026-09-09T00:27:30+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.